IDEXX Laboratories, Inc. (IDXX) Holdings Cut by Commonwealth Bank of Australia

Commonwealth Bank of Australia decreased its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 33.8% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,043 shares of the company’s stock after selling 533 shares during the quarter. Commonwealth Bank of Australia’s holdings in IDEXX Laboratories were worth $161,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in IDXX. Koch Industries Inc. boosted its stake in shares of IDEXX Laboratories by 44,533.1% during the 2nd quarter. Koch Industries Inc. now owns 1,399,248 shares of the company’s stock worth $1,391,000 after acquiring an additional 1,396,113 shares in the last quarter. Janus Henderson Group PLC boosted its stake in shares of IDEXX Laboratories by 486.4% during the 2nd quarter. Janus Henderson Group PLC now owns 1,131,902 shares of the company’s stock worth $182,711,000 after acquiring an additional 938,888 shares in the last quarter. BlackRock Inc. boosted its stake in shares of IDEXX Laboratories by 10.5% during the 2nd quarter. BlackRock Inc. now owns 7,100,374 shares of the company’s stock worth $1,146,142,000 after acquiring an additional 673,347 shares in the last quarter. Old Mutual Global Investors UK Ltd. purchased a new stake in shares of IDEXX Laboratories during the 2nd quarter worth approximately $83,723,000. Finally, Arrowstreet Capital Limited Partnership boosted its stake in shares of IDEXX Laboratories by 42.8% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 1,310,660 shares of the company’s stock worth $211,567,000 after acquiring an additional 392,790 shares in the last quarter. 86.80% of the stock is currently owned by institutional investors and hedge funds.

In related news, CEO Jonathan W. Ayers sold 18,000 shares of the company’s stock in a transaction that occurred on Thursday, November 16th. The stock was sold at an average price of $153.61, for a total value of $2,764,980.00. Following the sale, the chief executive officer now owns 1,064,573 shares of the company’s stock, valued at approximately $163,529,058.53. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Giovani Twigge sold 2,000 shares of the company’s stock in a transaction that occurred on Thursday, November 30th. The shares were sold at an average price of $156.07, for a total value of $312,140.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 110,000 shares of company stock worth $16,686,200. 2.77% of the stock is owned by corporate insiders.

Shares of IDEXX Laboratories, Inc. (NASDAQ IDXX) opened at $159.78 on Friday. IDEXX Laboratories, Inc. has a 52 week low of $113.92 and a 52 week high of $173.01. The company has a quick ratio of 0.77, a current ratio of 0.95 and a debt-to-equity ratio of -12.48. The stock has a market capitalization of $13,960.00, a P/E ratio of 53.80, a P/E/G ratio of 2.42 and a beta of 0.42.

IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Tuesday, October 31st. The company reported $0.79 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.74 by $0.05. IDEXX Laboratories had a negative return on equity of 336.64% and a net margin of 14.55%. The firm had revenue of $492.00 million for the quarter, compared to analyst estimates of $492.94 million. During the same quarter in the prior year, the company earned $0.62 EPS. IDEXX Laboratories’s revenue was up 9.7% on a year-over-year basis. equities analysts forecast that IDEXX Laboratories, Inc. will post 3.24 earnings per share for the current year.

Several brokerages have recently commented on IDXX. Zacks Investment Research raised IDEXX Laboratories from a “hold” rating to a “buy” rating and set a $184.00 price target on the stock in a research note on Tuesday, October 24th. Stifel Nicolaus reissued a “buy” rating and set a $185.00 price target on shares of IDEXX Laboratories in a research note on Tuesday, October 24th. Canaccord Genuity reissued a “buy” rating and set a $180.00 price target on shares of IDEXX Laboratories in a research note on Friday, October 6th. Finally, Bank of America raised IDEXX Laboratories from a “neutral” rating to a “buy” rating and set a $175.00 price target on the stock in a research note on Wednesday, August 23rd. Two research analysts have rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $173.67.

ILLEGAL ACTIVITY WARNING: This piece of content was first published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright laws. The legal version of this piece of content can be read at https://www.chaffeybreeze.com/2017/12/08/idexx-laboratories-inc-idxx-holdings-cut-by-commonwealth-bank-of-australia.html.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply